EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation Stock
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.72 USD | -1.01% |
|
+1.28% | +14.83% |
| Apr. 23 | Edwards Lifesciences Corporation: The story continues |  |
| Apr. 17 | Baird Adjusts Edwards Lifesciences Price Target to $102 From $100 | MT |
Financials (USD)
| Sales 2024 * | 6.52B | Sales 2025 * | 7.15B | Capitalization | 53.34B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.62B | Net income 2025 * | 1.82B | EV / Sales 2024 * | 7.9 x |
| Net cash position 2024 * | 1.87B | Net cash position 2025 * | 3.09B | EV / Sales 2025 * | 7.02 x |
| P/E ratio 2024 * |
33
x | P/E ratio 2025 * |
29.5
x | Employees | 19,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Edwards Lifesciences Corporation
More recommendations
More press releases
More news
| 1 day | +0.98% | ||
| 1 week | +1.57% | ||
| Current month | -7.27% | ||
| 1 month | -5.52% | ||
| 3 months | +22.15% | ||
| 6 months | +25.71% | ||
| Current year | +16.21% |
1 week
85.38
89.17
1 month
85.3896.12
Current year
71.6796.12
1 year
60.5796.12
3 years
60.57131.73
5 years
51.51131.73
10 years
13.02131.73
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 14-12-31 | |
| Chairman | 71 | 99-12-31 | |
Scott Ullem
DFI | Director of Finance/CFO | 57 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 63 | 16-07-04 |
| Director/Board Member | 67 | 14-11-12 | |
Steven Loranger
BRD | Director/Board Member | 72 | 16-03-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 44 M€ | +1.21% | - | |
| 2.34% | 18 M€ | +3.04% | - | |
| 2.13% | 6 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 87.58 | -1.16% | 1 274 746 |
| 24-04-24 | 88.61 | +0.98% | 3,234,988 |
| 24-04-23 | 87.75 | +0.91% | 2,663,641 |
| 24-04-22 | 86.96 | +1.19% | 2,408,082 |
| 24-04-19 | 85.94 | -0.59% | 3,895,701 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
04:15pm
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
88.61
USD
Average target price
94.48
USD
Spread / Average Target
+6.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.21% | 53.34B | |
| +8.78% | 220B | |
| +8.24% | 185B | |
| +11.16% | 133B | |
| +26.12% | 107B | |
| +0.30% | 62.91B | |
| -1.63% | 47.71B | |
| -1.11% | 40.29B | |
| +12.16% | 39.57B | |
| +6.84% | 26.99B |
- Stock Market
- Equities
- EW Stock
